Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications

摘要: Antibiotics are arguably the greatest medical development of 20th century but these precious resources being threatened by continued rise in infections caused multidrug-resistant bacteria. There is concern that we on precipice a 'post-antibiotic era'. The situation exacerbated stagnation pharmaceutical industry developing new antibiotics, particularly those with activity against some most resistant Gram-negative organisms because significant economic, scientific, and regulatory barriers. One products recent initiatives to reinvigorate antibiotic pipeline agent ceftolozane/tazobactam. Ceftolozane/tazobactam was approved December 2014 US Food Drug Administration for treatment complicated urinary tract intra-abdominal patients 18 years age older. safety effectiveness ceftolozane/tazobactam pediatric has not been established clinical studies. However, highly drug-resistant children current climate ongoing, multiple, simultaneous shortages--particularly broad-spectrum potential off-label role needs be explored while studies ongoing. objective this opinion piece discuss what currently known about its implications use population.